Abdul Hafeez
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Abdul Hafeez has a total of 30 co-authors. Here are the top co-authors by number of shared publications:
Archita Kapoor
Faculty of Pharmacy, Integral University, Lucknow - 226026, Uttar Pradesh, India
3 shared publications- Nargis Ara
Faculty of Pharmacy, Integral University, Lucknow- 226026, India
3 shared publications - Shazia Usmani
Department of Pharmacy, Integral University, Dasauli, Kursi Road, Lucknow 226026, India
3 shared publications Shom Prakash Kushwaha
Faculty of Pharmacy, Integral University, Lucknow-226026, India
3 shared publicationsMohd Hussain
Faculty of Pharmacy, Integral University
2 shared publications- Poonam Kushwaha
Faculty of Pharmacy, Integral University, Lucknow, India
2 shared publications
Latest Publications
- 25 March 2026
- Published by Bentham Science Publishers Ltd. in CNS & Neurological Disorders - Drug Targets
- Vol. 25
Solid Lipid Nanoparticle Mediated Intranasal Drug Delivery for Brain Targeting: A Comprehensive Review
The blood-brain barrier (BBB) restricts the passage of drugs into the brain, preventing drug transport to the central nervous system and minimizing the therapeutic effectiveness of several drugs used for brain diseases. The intranasal route of administration provides a non-invasive, quick, and efficient means of achieving direct brain targeting. The anatomy and physiology of the nasal cavity play a vital role in drug absorption and transport to the brain. The olfactory and trigeminal nerves are directly linked to the brain, allowing drugs to bypass the BBB. Solid Lipid Nanoparticles (SLNs) have emerged as a potential drug delivery system for the intranasal administration of therapeutic agents targeting brain diseases. SLNs are composed of biocompatible lipids and surfactants and offer unique advantages, such as controlled drug release, enhancement in bioavailability, and high brain targeting potential. This review focuses on the exploration of drug-loaded intranasally delivered SLNs for brain diseases (Alzheimer’s, Huntington’s, stroke, epilepsy, depression, meningitis, Parkinsonism, migraine, brain cancer) with emphasis on the in vitro and in vivo findings. In the reviewed literature, the size of drug-loaded SLNs for brain delivery via intranasal administration was found to be in the range of 65-210 nm. Ongoing clinical trials and patents involving SLNs for intranasal delivery further strengthen the enhanced interest in this drug delivery platform for the effective management of brain diseases.
- 25 March 2026
- Published by Bentham Science Publishers Ltd. in CNS & Neurological Disorders - Drug Targets
- Vol. 25
Solid Lipid Nanoparticle Mediated Intranasal Drug Delivery for Brain Targeting: A Comprehensive Review
The blood-brain barrier (BBB) restricts the passage of drugs into the brain, preventing drug transport to the central nervous system and minimizing the therapeutic effectiveness of several drugs used for brain diseases. The intranasal route of administration provides a non-invasive, quick, and efficient means of achieving direct brain targeting. The anatomy and physiology of the nasal cavity play a vital role in drug absorption and transport to the brain. The olfactory and trigeminal nerves are directly linked to the brain, allowing drugs to bypass the BBB. Solid Lipid Nanoparticles (SLNs) have emerged as a potential drug delivery system for the intranasal administration of therapeutic agents targeting brain diseases. SLNs are composed of biocompatible lipids and surfactants and offer unique advantages, such as controlled drug release, enhancement in bioavailability, and high brain targeting potential. This review focuses on the exploration of drug-loaded intranasally delivered SLNs for brain diseases (Alzheimer’s, Huntington’s, stroke, epilepsy, depression, meningitis, Parkinsonism, migraine, brain cancer) with emphasis on the in vitro and in vivo findings. In the reviewed literature, the size of drug-loaded SLNs for brain delivery via intranasal administration was found to be in the range of 65-210 nm. Ongoing clinical trials and patents involving SLNs for intranasal delivery further strengthen the enhanced interest in this drug delivery platform for the effective management of brain diseases.
- 17 March 2026
- Published by Bentham Science Publishers Ltd. in Micro and Nanosystems
- Vol. 18 (4) , 1-16
Berberine-Loaded Nanostructured Lipid Carriers for Transdermal Delivery: Box-Behnken Design-Assisted Optimization, In vitro, and In vivo Evaluation
Introduction: Berberine is an isoquinoline alkaloid with multiple therapeutic effects. Its salt, berberine chloride (BCL), has recently been explored for its effectiveness in diabetes. However, BCL exhibits poor water solubility and low permeability, which limits its oral bioavailability. The aim of this study was to optimize and evaluate a nanostructured lipid carrier (NLC)-based transdermal gel formulation of BCL. Methods: BCL-loaded NLCs were fabricated by high-speed homogenization followed by ultrasonication. The formulation was optimized using a three-level, three-factor Box-Behnken Design, with the concentration of surfactant, the ratio of solid to liquid lipid, and the total lipid concentration as independent variables. Entrapment efficiency (%) and flux (μg/cm²/h) were selected as dependent variables. Particle size, polydispersity index, entrapment efficiency, zeta potential, and permeation were all evaluated for the optimized formulation. After optimization, a gel formulation for transdermal application was developed and evaluated. Results: The optimized formulation showed a particle size of 665.5 ± 5.23 nm, zeta potential of - 46.6 mV, and entrapment efficiency of 71.18 ± 1.89%. In vitro release studies revealed prolonged and high drug release from the NLC-based gel (78.73 ± 0.46%) compared to the conventional gel (46.08 ± 0.39%) formulation of BCL. The NLC-based gel demonstrated higher permeation (28.53 ± 1.17 μg/cm²/h) of BCL through mouse skin compared with the conventional gel formulation (9.31 ± 0.26 μg/cm²/h). The gel formulation was stable at 30°C/70% relative humidity after 3 months of storage. Animal studies using female Swiss mice exhibited a significant reduction in hyperglycemia after transdermal application of the NLC-based gel of BCL (101 ± 5 mg/dL) compared to the conventional gel formulation (143 ± 6 mg/dL). Discussion: This study successfully optimized and evaluated BCL-NLC for transdermal drug delivery. Sustained drug release was observed due to the entrapment of BCL within the NLC matrix. The components of NLCs enhanced the permeation of BCL through the mice skin compared to the conventional gel formulation. The developed NLC formulation exhibited improved anti-hyperglycemic activity due to enhanced skin permeation in vivo. Conclusion: The developed NLC gel of BCL holds potential as an efficient therapeutic approach for the management of diabetes.
- 17 March 2026
- Published by Bentham Science Publishers Ltd. in Micro and Nanosystems
- Vol. 18 (4) , 1-16
Berberine-Loaded Nanostructured Lipid Carriers for Transdermal Delivery: Box-Behnken Design-Assisted Optimization, In vitro, and In vivo Evaluation
Introduction: Berberine is an isoquinoline alkaloid with multiple therapeutic effects. Its salt, berberine chloride (BCL), has recently been explored for its effectiveness in diabetes. However, BCL exhibits poor water solubility and low permeability, which limits its oral bioavailability. The aim of this study was to optimize and evaluate a nanostructured lipid carrier (NLC)-based transdermal gel formulation of BCL. Methods: BCL-loaded NLCs were fabricated by high-speed homogenization followed by ultrasonication. The formulation was optimized using a three-level, three-factor Box-Behnken Design, with the concentration of surfactant, the ratio of solid to liquid lipid, and the total lipid concentration as independent variables. Entrapment efficiency (%) and flux (μg/cm²/h) were selected as dependent variables. Particle size, polydispersity index, entrapment efficiency, zeta potential, and permeation were all evaluated for the optimized formulation. After optimization, a gel formulation for transdermal application was developed and evaluated. Results: The optimized formulation showed a particle size of 665.5 ± 5.23 nm, zeta potential of - 46.6 mV, and entrapment efficiency of 71.18 ± 1.89%. In vitro release studies revealed prolonged and high drug release from the NLC-based gel (78.73 ± 0.46%) compared to the conventional gel (46.08 ± 0.39%) formulation of BCL. The NLC-based gel demonstrated higher permeation (28.53 ± 1.17 μg/cm²/h) of BCL through mouse skin compared with the conventional gel formulation (9.31 ± 0.26 μg/cm²/h). The gel formulation was stable at 30°C/70% relative humidity after 3 months of storage. Animal studies using female Swiss mice exhibited a significant reduction in hyperglycemia after transdermal application of the NLC-based gel of BCL (101 ± 5 mg/dL) compared to the conventional gel formulation (143 ± 6 mg/dL). Discussion: This study successfully optimized and evaluated BCL-NLC for transdermal drug delivery. Sustained drug release was observed due to the entrapment of BCL within the NLC matrix. The components of NLCs enhanced the permeation of BCL through the mice skin compared to the conventional gel formulation. The developed NLC formulation exhibited improved anti-hyperglycemic activity due to enhanced skin permeation in vivo. Conclusion: The developed NLC gel of BCL holds potential as an efficient therapeutic approach for the management of diabetes.
- 1 October 2025
- Published by Bentham Science Publishers Ltd. in Recent Advances in Drug Delivery and Formulation
- Vol. 19 (4) , 327-352
Drug Delivery through Co-amorphous Solid Dispersions: A Comprehensive and Updated Review on Physicochemical Characteristics and Biological Potential
New chemical entities with low aqueous solubility and permeability encounter significant challenges in formulation development. Low solubility is further accompanied by slow dissolution and poor bioavailability, which in turn leads to unpredictability in terms of both bioavailability and toxicity. Therefore, a significant amount of exertion is necessary to enhance solubility, dissolution, and eventually bioavailability. Additionally, to enhance the solubility properties and amorphous stability of BCS Class II medications and ultimately increase drug bioavailability, coamorphization has emerged as a promising strategy. Co-amorphous solid dispersions (CASD) are multi-component single-phase amorphous solid dispersions comprising two or more small molecules (usually known as co-formers) that might be a combination of drug-drug or drug-excipients. The selection of appropriate co-formers is critical, and the surface properties of co-amorphous formulations must be carefully evaluated, as they influence physical and chemical stability in addition to dissolution performance. Scaling up and processing co-amorphous formulations into the final dosage forms presents challenges that need to be addressed. This review will largely concentrate on the challenges, improvements, and innovations in physicochemical properties, biological characterization, and advancements of co-amorphous systems. This review will also furnish a comprehensive explanation of both established and emerging approaches utilized in the estimation of physicochemical attributes and characterization of CASD (in vitro and in vivo). Regarding CASD’s potential to improve patient outcomes and therapeutic efficacy, it has emerged as a viable approach for drug candidates posing the problems of solubility and bioavailability. This approach has also increased the physical stability of drugs.
- 1 October 2025
- Published by Bentham Science Publishers Ltd. in Recent Advances in Drug Delivery and Formulation
- Vol. 19 (4) , 327-352
Drug Delivery through Co-amorphous Solid Dispersions: A Comprehensive and Updated Review on Physicochemical Characteristics and Biological Potential
New chemical entities with low aqueous solubility and permeability encounter significant challenges in formulation development. Low solubility is further accompanied by slow dissolution and poor bioavailability, which in turn leads to unpredictability in terms of both bioavailability and toxicity. Therefore, a significant amount of exertion is necessary to enhance solubility, dissolution, and eventually bioavailability. Additionally, to enhance the solubility properties and amorphous stability of BCS Class II medications and ultimately increase drug bioavailability, coamorphization has emerged as a promising strategy. Co-amorphous solid dispersions (CASD) are multi-component single-phase amorphous solid dispersions comprising two or more small molecules (usually known as co-formers) that might be a combination of drug-drug or drug-excipients. The selection of appropriate co-formers is critical, and the surface properties of co-amorphous formulations must be carefully evaluated, as they influence physical and chemical stability in addition to dissolution performance. Scaling up and processing co-amorphous formulations into the final dosage forms presents challenges that need to be addressed. This review will largely concentrate on the challenges, improvements, and innovations in physicochemical properties, biological characterization, and advancements of co-amorphous systems. This review will also furnish a comprehensive explanation of both established and emerging approaches utilized in the estimation of physicochemical attributes and characterization of CASD (in vitro and in vivo). Regarding CASD’s potential to improve patient outcomes and therapeutic efficacy, it has emerged as a viable approach for drug candidates posing the problems of solubility and bioavailability. This approach has also increased the physical stability of drugs.
- 2 August 2025
- Published by A and V Publications in Research Journal of Pharmacy and Technology
- Vol. 18 (8) , 3742-3748
UV-Vis Spectrophotometric Method of Amantadine Hydrochloride Analysis: Method Development, Validation and Application to Solubility Studies
The goal of the current work was to develop a sensitive UV-Vis spectrophotometric method for estimation of amantadine hydrochloride. A safe, precise, quick, easy, affordable and effective approach by derivatizing an aliphatic cyclic primary amine drug moiety was designed, since it lacks a chromophoric functional group. The 1,2-naphthoquinone-4-sulphonate reagent was used for derivatization due to its high affinity towards primary amine group. The maximum absorption wavelength obtained was 433nm. The limit of detection obtained was 0.35μg/ml. The linearity was assessed in between 2-20μg/ml with good correlation coefficient of 0.9983. Each parameter was analyzed within the developed range, and the percent relative standard deviation was found to be below 2%, which indicated accuracy of the developed method for different parameters. The validated approach was applied for the analysis of amantadine hydrochloride's solubility in solid lipids (glyceryl monostearate, stearic acid and beeswax), liquid lipids (eucalyptus oil, oleic acid, isopropyl myristate and castor oil) and surfactants (Tween-80, Tween-20 and Span-80). The drug showed highest solubility in Glyceryl monostearate (40.36mg/g), eucalyptus oil (3.45mg/ml) and Tween-20(3.47mg/ml). The resulted outcomes demonstrated the method's applicability for quantitative estimation of amantadine hydrochloride in future studies. Solid lipids, liquid lipids and surfactants may be analyzed precisely by the developed method.
- 2 August 2025
- Published by A and V Publications in Research Journal of Pharmacy and Technology
- Vol. 18 (8) , 3742-3748
UV-Vis Spectrophotometric Method of Amantadine Hydrochloride Analysis: Method Development, Validation and Application to Solubility Studies
The goal of the current work was to develop a sensitive UV-Vis spectrophotometric method for estimation of amantadine hydrochloride. A safe, precise, quick, easy, affordable and effective approach by derivatizing an aliphatic cyclic primary amine drug moiety was designed, since it lacks a chromophoric functional group. The 1,2-naphthoquinone-4-sulphonate reagent was used for derivatization due to its high affinity towards primary amine group. The maximum absorption wavelength obtained was 433nm. The limit of detection obtained was 0.35μg/ml. The linearity was assessed in between 2-20μg/ml with good correlation coefficient of 0.9983. Each parameter was analyzed within the developed range, and the percent relative standard deviation was found to be below 2%, which indicated accuracy of the developed method for different parameters. The validated approach was applied for the analysis of amantadine hydrochloride's solubility in solid lipids (glyceryl monostearate, stearic acid and beeswax), liquid lipids (eucalyptus oil, oleic acid, isopropyl myristate and castor oil) and surfactants (Tween-80, Tween-20 and Span-80). The drug showed highest solubility in Glyceryl monostearate (40.36mg/g), eucalyptus oil (3.45mg/ml) and Tween-20(3.47mg/ml). The resulted outcomes demonstrated the method's applicability for quantitative estimation of amantadine hydrochloride in future studies. Solid lipids, liquid lipids and surfactants may be analyzed precisely by the developed method.
- Open Access
- 7 July 2025
- Published by Innovare Academic Sciences Pvt Ltd in International Journal of Applied Pharmaceutics
- p. 497-510
REPURPOSED SIMVASTATIN-LOADED NANOSTRUCTURED LIPID CARRIERS: OPTIMIZATION, CHARACTERIZATION AND EVALUATION AGAINST LUNG CANCER
Objective: Repurposed Simvastatin (SMV) is being investigated for the treatment of lung malignancies. However, its inadequate solubility in water and formulation constraints are the potential challenges for its use against lung cancer. This study aimed at synthesis of SMV-loaded Nanostructured Lipid Carriers (SMV-NLC) for lung cancer management. Methods: Emulsification and probe sonication approach was chosen for the formulation of NLCs. A three-factor, three-level Box-Behnken design was utilized for the development of SMV-NLC formulation. The independent variables selected were total lipid concentration (%w/w), solid lipid: liquid lipid ratio, and surfactant concentration (%w/w). Screening of components was performed based on SMV solubility and SMV-excipient compatibility studies. Results: Optimized SMV-NLC showed a particle size of 209.8±1.8 nm, low polydispersity index (0.319±0.14), negative zeta potential (-20.35 mV) and good entrapment efficiency (73.51±4.22%). Transmission electron microscopy examination revealed spherical shape of NLC with validation of nanometric size. Fourier Transform Infrared analysis revealed the entrapment of the SMV within the lipid matrix of NLC. SMV release of 86.97±1.7% was obtained from NLC after 24 h with sustained release characteristics. In vitro cytotoxic activity against A549 cell lines (lung cancer) showed IC50of 11.34±0.12 and 30.26±0.14 µg/ml for SMV-NLC and SMV-suspension, respectively. Conclusion: The developed SMV-NLC may be utilized as an effective platform for the management of lung cancer.
- 7 July 2025
- Published by Innovare Academic Sciences Pvt Ltd in International Journal of Applied Pharmaceutics
- p. 497-510
Open AccessREPURPOSED SIMVASTATIN-LOADED NANOSTRUCTURED LIPID CARRIERS: OPTIMIZATION, CHARACTERIZATION AND EVALUATION AGAINST LUNG CANCER
Objective: Repurposed Simvastatin (SMV) is being investigated for the treatment of lung malignancies. However, its inadequate solubility in water and formulation constraints are the potential challenges for its use against lung cancer. This study aimed at synthesis of SMV-loaded Nanostructured Lipid Carriers (SMV-NLC) for lung cancer management. Methods: Emulsification and probe sonication approach was chosen for the formulation of NLCs. A three-factor, three-level Box-Behnken design was utilized for the development of SMV-NLC formulation. The independent variables selected were total lipid concentration (%w/w), solid lipid: liquid lipid ratio, and surfactant concentration (%w/w). Screening of components was performed based on SMV solubility and SMV-excipient compatibility studies. Results: Optimized SMV-NLC showed a particle size of 209.8±1.8 nm, low polydispersity index (0.319±0.14), negative zeta potential (-20.35 mV) and good entrapment efficiency (73.51±4.22%). Transmission electron microscopy examination revealed spherical shape of NLC with validation of nanometric size. Fourier Transform Infrared analysis revealed the entrapment of the SMV within the lipid matrix of NLC. SMV release of 86.97±1.7% was obtained from NLC after 24 h with sustained release characteristics. In vitro cytotoxic activity against A549 cell lines (lung cancer) showed IC50of 11.34±0.12 and 30.26±0.14 µg/ml for SMV-NLC and SMV-suspension, respectively. Conclusion: The developed SMV-NLC may be utilized as an effective platform for the management of lung cancer.
- 18 June 2025
- Published by Springer Nature in Journal of Nanoparticle Research
- Vol. 27 (7) , 1-44
Intranasal delivery of drug-loaded polymeric nanomicelles for brain targeting: a comprehensive review
- 18 June 2025
- Published by Springer Nature in Journal of Nanoparticle Research
- Vol. 27 (7) , 1-44
Intranasal delivery of drug-loaded polymeric nanomicelles for brain targeting: a comprehensive review
- Open Access
- 6 June 2025
- Published by Oriental Scientific Publishing Company in Oriental Journal of Chemistry
- Vol. 41 (3) , 1053-1066
Development and Validation of a Novel and Robust RP-HPLC Method for the Simultaneous Estimation of Metformin and Sesamol, and its Application in an In-house Developed Nanoliposomal Formulation
This study introduces a unique High-Performance Liquid Chromatography (HPLC) method for quantifying Metformin and Sesamol simultaneously in pharmaceuticals. The technique uses a reverse-phase C18 column with acetonitrile and water in a gradient pattern with UV detection. The method demonstrated good linearity for Metformin and Sesamol at concentrations ranging from 20-1.25 μg/ml, with coefficients of correlation (r²) of 0.9947 and 0.9908, respectively. The method demonstrated excellent repeatability, with precision measured as RSD below 2% for intra-day and inter-day measurements. The method's accuracy was proven through recovery tests. The Metformin's LOD and LOQ reported as 0.89 μg/mL & 2.71 μg/ml, and Sesamol's as 1.27 μg/ml & 3.86 μg/ml, respectively. The approach also demonstrated resilience to minor fluctuations in method parameters, making it suitable for regular analysis. This validated HPLC technique was successfully used for the simultaneous measurement of Metformin and Sesamol in a nanoliposomal formulation, providing a reliable tool for quality control.
- 6 June 2025
- Published by Oriental Scientific Publishing Company in Oriental Journal of Chemistry
- Vol. 41 (3) , 1053-1066
Open AccessDevelopment and Validation of a Novel and Robust RP-HPLC Method for the Simultaneous Estimation of Metformin and Sesamol, and its Application in an In-house Developed Nanoliposomal Formulation
This study introduces a unique High-Performance Liquid Chromatography (HPLC) method for quantifying Metformin and Sesamol simultaneously in pharmaceuticals. The technique uses a reverse-phase C18 column with acetonitrile and water in a gradient pattern with UV detection. The method demonstrated good linearity for Metformin and Sesamol at concentrations ranging from 20-1.25 μg/ml, with coefficients of correlation (r²) of 0.9947 and 0.9908, respectively. The method demonstrated excellent repeatability, with precision measured as RSD below 2% for intra-day and inter-day measurements. The method's accuracy was proven through recovery tests. The Metformin's LOD and LOQ reported as 0.89 μg/mL & 2.71 μg/ml, and Sesamol's as 1.27 μg/ml & 3.86 μg/ml, respectively. The approach also demonstrated resilience to minor fluctuations in method parameters, making it suitable for regular analysis. This validated HPLC technique was successfully used for the simultaneous measurement of Metformin and Sesamol in a nanoliposomal formulation, providing a reliable tool for quality control.
- 1 January 2025
- Published by American Association for the Advancement of Science (AAAS) in Journal of Bio-X Research
- Vol. 8
Zingerone-Encapsulated Nanoethosomes for Transdermal Delivery: Factorial Design-Assisted Optimization and Evaluation for Systemic Drug Delivery
Transdermal drug delivery offers the benefits of first-pass metabolism avoidance, high bioavailability, a low dose, and high patient compliance. Ethosomes are lipid-based vesicles containing phospholipids, ethanol, and water that enhance drug penetration by overcoming the barrier of the skin. Ethosomes can encapsulate lipophilic as well as hydrophilic drugs to increase their efficacy. Zingerone (ZNE) is a major component found in gingerroot and has potent antidiabetic, antioxidant, and antispasmodic activities. ZNE has low solubility in aqueous media, which leads to low oral bioavailability. ZNE-loaded ethosomes were prepared via the cold method. The ethosomes were optimized by a 3-level and 2-factor full factorial design. The independent variables selected were ethanol (%) and soy lecithin (%). The dependent variables selected were flux (μg/cm 2 /h) and entrapment efficiency (%). The optimized formulation was evaluated for size, polydispersity index, zeta potential, entrapment efficiency, in vitro drug release, and ex vivo skin drug permeation. The optimized formulation had an average vesicle size of 77.12 ± 1.89 nm, a polydispersity index of 0.350 ± 0.013, a zeta potential of −56.9 ± 1.25 mV, an entrapment efficiency of 75.83% ± 1.53%, in vitro drug release of 85.97% ± 1.92% (after 24 h), and ex vivo skin drug permeation of 78.52% ± 1.62%. The optimized formulation was converted to a gel formulation and characterized for in vitro parameters. The percent permeation of ZNE through rat skin (ex vivo) from the ethosomal gel was greater (73.12% ± 1.76%) than that from the conventional gel (38.17% ± 1.82%). This study reveals the substantial potential of ZNE-loaded ethosomes for transdermal delivery and for use in the management of systemic diseases.
- 1 January 2025
- Published by American Association for the Advancement of Science (AAAS) in Journal of Bio-X Research
- Vol. 8
Zingerone-Encapsulated Nanoethosomes for Transdermal Delivery: Factorial Design-Assisted Optimization and Evaluation for Systemic Drug Delivery
Transdermal drug delivery offers the benefits of first-pass metabolism avoidance, high bioavailability, a low dose, and high patient compliance. Ethosomes are lipid-based vesicles containing phospholipids, ethanol, and water that enhance drug penetration by overcoming the barrier of the skin. Ethosomes can encapsulate lipophilic as well as hydrophilic drugs to increase their efficacy. Zingerone (ZNE) is a major component found in gingerroot and has potent antidiabetic, antioxidant, and antispasmodic activities. ZNE has low solubility in aqueous media, which leads to low oral bioavailability. ZNE-loaded ethosomes were prepared via the cold method. The ethosomes were optimized by a 3-level and 2-factor full factorial design. The independent variables selected were ethanol (%) and soy lecithin (%). The dependent variables selected were flux (μg/cm 2 /h) and entrapment efficiency (%). The optimized formulation was evaluated for size, polydispersity index, zeta potential, entrapment efficiency, in vitro drug release, and ex vivo skin drug permeation. The optimized formulation had an average vesicle size of 77.12 ± 1.89 nm, a polydispersity index of 0.350 ± 0.013, a zeta potential of −56.9 ± 1.25 mV, an entrapment efficiency of 75.83% ± 1.53%, in vitro drug release of 85.97% ± 1.92% (after 24 h), and ex vivo skin drug permeation of 78.52% ± 1.62%. The optimized formulation was converted to a gel formulation and characterized for in vitro parameters. The percent permeation of ZNE through rat skin (ex vivo) from the ethosomal gel was greater (73.12% ± 1.76%) than that from the conventional gel (38.17% ± 1.82%). This study reveals the substantial potential of ZNE-loaded ethosomes for transdermal delivery and for use in the management of systemic diseases.
- 21 October 2024
- Published by Springer Nature in AAPS PharmSciTech
- Vol. 25 (8) , 1-25
Demystifying the Potential of Embelin-Loaded Nanoformulations: a Comprehensive Review
Phytoconstituent based therapies have the potential to reduce the adverse effects and enhance overall patient compliance for different diseased conditions.
- 21 October 2024
- Published by Springer Nature in AAPS PharmSciTech
- Vol. 25 (8) , 1-25
Demystifying the Potential of Embelin-Loaded Nanoformulations: a Comprehensive Review
Phytoconstituent based therapies have the potential to reduce the adverse effects and enhance overall patient compliance for different diseased conditions.